Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "inclusion"

89 News Found

Kaiser Permanente’s study highlights power of genetics in preventing heart disease
R&D | November 14, 2025

Kaiser Permanente’s study highlights power of genetics in preventing heart disease

Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD


BASF and Beyond Suncare welcome WHO decision to list broad-spectrum sunscreen as “Essential Medicine”
News | November 12, 2025

BASF and Beyond Suncare welcome WHO decision to list broad-spectrum sunscreen as “Essential Medicine”

The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance


Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices
Policy | November 11, 2025

Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices

Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans


AstraZeneca invests additional $136 million to expand Qingdao inhalants facility
News | November 07, 2025

AstraZeneca invests additional $136 million to expand Qingdao inhalants facility

This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million


Merck advances cancer innovation by expanding role of Keytruda across new tumor
R&D | October 11, 2025

Merck advances cancer innovation by expanding role of Keytruda across new tumor

The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025


BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu
News | September 30, 2025

BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu

Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price


Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada
News | September 22, 2025

Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada


Biocon Foundation launches BioWISE Program to empower women in STEM
News | June 11, 2025

Biocon Foundation launches BioWISE Program to empower women in STEM

25 women students to receive internship, training, and mentorship in Life Sciences segment


Lupin secures a place in S&P Global Sustainability Yearbook 2025
Sustainability | February 28, 2025

Lupin secures a place in S&P Global Sustainability Yearbook 2025

Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score